177 related articles for article (PubMed ID: 9040924)
1. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.
Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
Can J Psychiatry; 1997 Feb; 42(1):53-7. PubMed ID: 9040924
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic drug doses in a schizophrenia inpatient unit.
Galletly CA
Aust N Z J Psychiatry; 1992 Dec; 26(4):574-6. PubMed ID: 1362051
[TBL] [Abstract][Full Text] [Related]
3. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.
Peralta V; Cuesta MJ; Caro F; Martinez-Larrea A
Acta Psychiatr Scand; 1994 Nov; 90(5):354-7. PubMed ID: 7872040
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic medication in the treatment of schizophrenia.
Kane JM
Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic medication: clinical guidelines for maintenance therapy.
Johnson DA
J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
[TBL] [Abstract][Full Text] [Related]
6. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
[TBL] [Abstract][Full Text] [Related]
7. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study.
Takeuchi H; Uchida H; Suzuki T; Watanabe K; Kashima H
J Clin Psychopharmacol; 2009 Aug; 29(4):394-5. PubMed ID: 19593185
[No Abstract] [Full Text] [Related]
8. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
Leblanc G; Cormier H; Gagné MA; Vaillancourt S
Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
[TBL] [Abstract][Full Text] [Related]
9. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
[TBL] [Abstract][Full Text] [Related]
10. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
11. The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavourable long-term course. A 5-year follow-up study of 50 chronic schizophrenics.
Beckmann H; Fritze J; Franzek E
Neuropsychobiology; 1992; 26(1-2):50-8. PubMed ID: 1361971
[TBL] [Abstract][Full Text] [Related]
12. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia.
Suzuki T; Uchida H; Tanaka KF; Nomura K; Takano H; Tanabe A; Watanabe K; Yagi G; Kashima H
Int J Neuropsychopharmacol; 2004 Jun; 7(2):133-42. PubMed ID: 14741059
[TBL] [Abstract][Full Text] [Related]
13. Ideal and reality of neuroleptic relapse prevention.
Kissling W
Br J Psychiatry Suppl; 1992 Oct; (18):133-9. PubMed ID: 1356363
[No Abstract] [Full Text] [Related]
14. Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics.
Gagné MA; Cormier H; Leblanc G; Lévesque D; Di Paolo T
Can J Psychiatry; 1993 Oct; 38(8):534-40. PubMed ID: 7902199
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients.
Tuninger E; Levander S
Acta Psychiatr Scand; 1997 Nov; 96(5):347-53. PubMed ID: 9395152
[TBL] [Abstract][Full Text] [Related]
16. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
Dassa D; Lacambre M; Vacheron MN
Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
[No Abstract] [Full Text] [Related]
17. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP].
Buis C; Gourion D; Vaiva G
Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185
[No Abstract] [Full Text] [Related]
18. A decision analysis approach to neuroleptic dosing: insights from a mathematical model.
Mossman D
J Clin Psychiatry; 1997 Feb; 58(2):66-73. PubMed ID: 9062375
[TBL] [Abstract][Full Text] [Related]
19. Neuroleptic dose reduction in older psychotic patients.
Harris MJ; Heaton RK; Schalz A; Bailey A; Patterson TL
Schizophr Res; 1997 Oct; 27(2-3):241-8. PubMed ID: 9416653
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years.
Linden M; Godemann F; Gaebel W; Köpke W; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
Schizophr Bull; 2001; 27(4):585-96. PubMed ID: 11824485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
